ArticleCardiorenal medicine2026
The Relationship between Sarcopenia and All-Cause and Cardiovascular Mortality Risk among Middle-Aged and Older Adults across Stages 0-3 of Cardiovascular-Kidney-Metabolic Syndrome: Evidence from NHANES and CHARLS.
Article in Cardiorenal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a nomogram for identifying prevalent sarcopenia in Chinese patients with Cardiovascular-Kidney-Metabolic Syndrome.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcopenia has been proved to be associated with cardiovascular diseases (CVD), chronic kidney disease, and metabolic disorders, but the relationship between sarcopenia and all-cause and cardiovascular mortality risk among middle-aged and older adults across stages 0-3 of cardiovascular-kidney-metabolic (CKM) syndrome remains unclear. This study aimed to investigate the relationship between sarcopenia and all-cause and cardiovascular mortality risk among middle-aged and older adults across stages 0-3 of CKM syndrome based on Nutrition Examination Survey (NHANES) 2011-2018 and the China Health and Retirement Longitudinal Study (CHARLS) 2011-2020.
methodsMultivariable Cox regression analysis was performed to analyze the association of sarcopenia with all-cause and CVD mortality. Restricted cubic spline (RCS) analysis was conducted to explore the non-linear relationship between body mass index (BMI)-adjusted muscle mass (appendicular skeletal muscle mass divided by BMI, ASMI) and all-cause and CVD mortality, and machine learning (ML) models were developed for mortality risk prediction. The CHARLS database was utilized as validation to enhance the stability of the results.
resultsOver an average follow-up of 5.11 years, NHANES recorded 85 all-cause deaths and 12 CVD deaths. After the full adjustment, sarcopenia was significantly associated with all-cause mortality (weighted hazard ratio [HR] = 3.428, 95% confidence interval [CI] 1.484-7.915, p = 0.004) and CVD mortality (weighted HR = 1.070, 95% CI 1.009-1.570, p = 0.049). RCS analysis revealed a nonlinear negative relationship between ASMI and CVD mortality (p for nonlinear = 0.009). ML models demonstrated better predictive performance, with random forest (area under the curve = 0.766) achieving the highest accuracy. In the CHARLS cohort, sarcopenia significantly increases all-cause mortality (HR = 2.519, 95% CI 1.402-4.527, p < 0.001), and subgroup analysis reported consistent results with the main analysis.
conclusionSarcopenia was significantly associated with all-cause mortality and with CVD mortality in fully adjusted models, though the latter association was modest, and exhibits good predictive performance for mortality among middle-aged and older individuals within CKM stages 0-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.